The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in patients 2 years and older with confirmed mutation in the survival motor neuron 1 (SMN1) gene.
Continue Reading
News Source: medicalxpress.com
Leave a Reply